13.98
+7.37%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Ortin Global
Its shares trade on NSE under the ticker ORTINGLOBE.NS. It has been listed since 15 November 1996. In the fiscal year to 31 March 2026, it reported revenue of ₹1.0m and a net loss of ₹7.4m. At that date it held total assets of ₹46.5m and shareholders' equity of ₹12.4m.
Ortin Laboratories Ltd. engages in the manufacture of drug intermediates and pharmaceuticals products. The company is headquartered in Hyderabad, Telangana. The company manufactures a range of pharmaceutical formulations of tablets, capsules, syrups, and dry powders. The firm's products include Acefinac, ACEFINAC-CZ, ACEFINAC-P, ACEFINAC-SP, ACTAZID, ACTY-P, ALERFEX-120, ALERFEX-180, ALERGID, ALERGID- L, AMLOBID, CARBAMOL, CARISNIL, CALDY-C AZITIN-500, DOCEF-200, GLYCITROL, GLYCITROL-M, LORACT, MEBOL, NEUROCOB, FERUP, IRFER Z, MINVITA-B, NILCID, ORICILLIN-DX, PEG POWDER, PEG-D POWDER, ALKASIT, COF-XL, DECODIL, ENCENIL and OROMOX DRY SYRUP. Its formulations include Anti Diabetics, Anti Allergics, Anti Anginal and Cardiovascular, Analgesics and Antipyretics, and Anti Biotics-Quinolones. Its active pharmaceutical ingredient (API) intermediates include Anti retro viral, Grignard, Diborane, Ciprofloxacin and Tramadol. The company is also manufacturing for different importers to market their products in Russia, Ukraine, Kajakistan and South America.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 15 Nov 1996
- Website
- ortinlabsindia.com ↗
Leadership
Pay as last reported
- Mr. Sarang PatodekarIndependent Chairman of the Board
- Shri. Sanka Krishna MurthyChief Executive Officer, Acting Compliance Officer, Managing Director, since 2024₹720,000
- Mr. Wani MadanlalChief Financial Officer
- Shri. Sanka VenkateswarluDirector - Marketing, Whole Time Director₹720,000
- Datla RajuWhole Time Director, since 2011
- Mrs. Prakruti SawantAdditional Whole-Time Director, since 2025
- Mr. Prashant SawantAdditional Whole-Time Director, since 2025
- Mr. Ajay VishwakarmaAdditional Executive Director, since 2025
- Mr. Pramod WagheNon-Executive Non-Independent Director
- Ms. Pammi ReddyAdditional Non-Executive Independent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- The company manufactures a wide range of pharmaceutical formulations.
- It produces active pharmaceutical ingredient intermediates.
- The firm supplies products to importers in multiple countries.
Weaknesses
- The source description is treated as untrusted facts.
- Specific financial data points are not provided.
- Market share details are absent from the text.
Opportunities
- Expansion into new international markets is possible.
- Diversification of the product portfolio can occur.
- Investment in new API technologies offers growth.
Threats
- Regulatory changes in target countries may impact sales.
- Competition from other pharmaceutical manufacturers exists.
- Economic instability in export regions poses risks.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.